رونوشت 🔗
WEBVTT
00:00:06.400 --> 00:00:14.560
Hello, and welcome to another podcast episode of The Telltale Heart, Pharmacy Times' Cardiovascular Digest for Pharmacists.
00:00:14.560 --> 00:00:16.079
I'm your host, Craig Beavers.
00:00:16.079 --> 00:00:23.120
As always, if before we get into the guests and conversations, if you like our content, you know, like, subscribe, give us feedback.
00:00:23.120 --> 00:00:29.519
We're always trying to add, change, modify, do things, get new uh guests and do those things.
00:00:29.519 --> 00:00:30.640
So please let us know.
00:00:30.640 --> 00:00:32.399
I have an exciting episode today.
00:00:32.399 --> 00:00:40.159
As you may see at the studio, we are here at the National Lipid Association meeting here in Orlando, Florida, uh, for their updates meeting.
00:00:40.159 --> 00:00:45.200
We're going to be partnering today with the Lipid Insides Podcast, the National Lipid Association podcast.
00:00:45.200 --> 00:00:49.359
And I'm very excited to have uh the guest with us today.
00:00:49.359 --> 00:00:59.520
Worked with him a lot, great colleague in peer, and excited to get his perspective as a lipidologist and an expert uh to bring to you as the pharmacy audience of that.
00:00:59.520 --> 00:01:01.359
So I'm gonna allow him to introduce himself.
00:01:01.359 --> 00:01:02.240
So uh Dr.
00:01:02.240 --> 00:01:05.439
Michael Wilson, would you like to introduce yourself, where you're at, and what you do?
00:01:05.439 --> 00:01:06.480
So sure.
00:01:06.640 --> 00:01:07.840
Well, thanks again for the invitation.
00:01:07.840 --> 00:01:08.719
Great to be with you.
00:01:08.719 --> 00:01:09.920
I'm Michael Wilkinson.
00:01:09.920 --> 00:01:18.400
I'm a cardiologist, I'm an associate professor of medicine at UC San Diego, and I run our lipid clinic there, our advanced lipid disorders treatment program.
00:01:18.959 --> 00:01:19.519
Very good.
00:01:19.519 --> 00:01:26.799
So, you know, since we're here, and it's been such an exciting year for lipid management, if you think about it.
00:01:26.799 --> 00:01:38.719
And I I think the the obvious topic of change or at least update that has come out and to provide a foundation for our conversation is the new set of guidelines that have come out within the last year.
00:01:38.719 --> 00:01:56.959
And so, you know, briefly in your mind, if you're thinking about it as a lipidologist, what are the highlighted changes that you would like to share from your perspective that maybe a pharmacist would be interested in, if they've looked at them or not, just from your perspective, these are the big things that have changed in my mind for practice.
00:01:56.959 --> 00:01:59.599
And and what what do you contextualize those as?
00:02:00.319 --> 00:02:10.159
So I think two of the biggest things to come out of the updated guidelines are the way that we approach risk stratification and then the way that we choose treatment targets and how to get to those targets.
00:02:10.159 --> 00:02:10.639
Right.
Load full transcript
00:02:10.639 --> 00:02:19.520
So from risk stratification, that's the introduction of the prevent equations into our dislipidemia guidelines that prevent ASCBD equations.
00:02:19.520 --> 00:02:35.280
And then according to our assessment of risk with those equations, with other risk-enhancing factors and use of imaging like calcium scoring, we choose treatment targets for LDL cholesterol, non-HDL cholesterol, and uh in many cases APOB as well.
00:02:35.599 --> 00:02:36.080
Very good.
00:02:36.080 --> 00:02:48.560
And you know, just to give you some context, when we originally did the podcast, we did an episode when the guidelines came out with Dave Dixon and Joe Sassine, who are on the guideline writing committee and kind of walk through the nitty-gritty of this.
00:02:48.560 --> 00:02:57.280
But just as a kind of refresher, you know, when you think about prevent prevent, and I always like to remind people there's a couple different versions of prevent.
00:02:57.280 --> 00:03:00.240
You got to make sure you're using the ASCVD risk score version of this.
00:03:00.240 --> 00:03:00.560
Right.
00:03:00.560 --> 00:03:10.319
What is the benefit for you, or what do you see uh the benefits as you have that conversation with your patients about now using prevent versus when we use the ASCVD risk score from that standpoint?
00:03:10.719 --> 00:03:23.520
I mean, I have shared with patients and with colleagues since the guidelines have come out that these are revised risk estimates that are derived from a larger number of patients and from different sources.
00:03:23.520 --> 00:03:30.879
So it's really an expanded tool that I think is uh even more representative of the population we care for.
00:03:30.879 --> 00:03:35.360
It also sets new thresholds for how to think about risk.
00:03:35.360 --> 00:03:43.599
So it's important to understand how the 10-year risk estimates and associated recommendations for treatment have shifted.
00:03:43.599 --> 00:03:52.719
So those borderline, intermediate, and high risk zones are a little bit different now in terms of the percent estimates for 10-year risk.
00:03:52.719 --> 00:03:57.680
But overall, I mean, it incorporates more information about the patient.
00:03:57.680 --> 00:04:04.159
Um, you know, there's more variables, there's the optional variables that add even further refinement to that 10-year risk.
00:04:04.159 --> 00:04:05.840
So I think those are some of the advantages.
00:04:06.479 --> 00:04:11.120
And obviously, prevent has a lower age threshold, for example, that we we look at that.
00:04:11.120 --> 00:04:17.680
How how are you uh really approaching that younger population now that you're you're having a lower age threshold to look at that?
00:04:18.079 --> 00:04:19.360
Yeah, that's a great question.
00:04:19.360 --> 00:04:27.040
I mean, I think that for those younger patients, the 10-year risk estimates from prevent are still useful, but they're often low.
00:04:27.040 --> 00:04:32.879
I mean, much like we
had with the pooled cohort equations, a lot of the the weight of that risk estimate comes from age.
00:04:32.879 --> 00:04:37.920
And so we're still getting for 10-year risk relatively low estimates for younger patients.
00:04:37.920 --> 00:04:40.879
But I think the 30-year risk is very helpful.
00:04:40.879 --> 00:04:41.199
Sure.
00:04:41.199 --> 00:04:44.560
And being able to apply that to younger patients is also helpful.
00:04:44.879 --> 00:04:45.839
And provide that conversation.
00:04:45.839 --> 00:04:47.040
It's interesting.
00:04:47.040 --> 00:04:55.519
Uh, you know, tomorrow I'm doing a talk here at NLA route and shared decision making, and this is obviously a key part of that having that type of conversation is what your your shared decision making with your rent score is.
00:04:55.519 --> 00:04:58.959
And I assume that's how you're incorporating that into your data flow.
00:04:59.279 --> 00:05:04.879
Yeah, and I think the the way to frame it for younger people is often with that longer horizon in mind.
00:05:04.879 --> 00:05:17.600
I mean, a 10-year risk estimate may only mean so much to somebody in their, you know, when they're in their late 30s or um, setting the conversation around your 30-year risk or lifetime risk.
00:05:17.600 --> 00:05:23.920
I mean, that's really what we should be talking about when we're counseling patients on the importance of lipid lowering over time.
00:05:23.920 --> 00:05:32.480
I mean, we know that the benefits come from lowering LDL and other athrogenic lipoproteins and keeping them at those lower levels over time.
00:05:32.480 --> 00:05:37.360
So we're talking about lifetime risk reduction and framing it that way, I think, is really important for younger patients.
00:05:37.680 --> 00:05:45.120
Yeah, I think you know, is more and more people or it's gaining steam and and we all need to think about it more about that long-term exposure, right?
00:05:45.120 --> 00:06:01.839
And not just the, oh, this is a point in time that we're thinking about and this is the fixed process, especially as we, I think, recognize more and more uh that um you know there is this longer-term exposure and that we're we're seeing that, and there's risk uh established that it's kind of interesting.
00:06:01.839 --> 00:06:10.879
Uh I don't know if you saw this, you probably saw the study at ESC that was looking at where they did the CT scanning amongst all the patients and kind of correlate it with various risk scores.
00:06:10.879 --> 00:06:22.879
And even the risk scores do a decent job, but there's still even evidence of disease way before that we see in some of the risk scores, even that younger population, and that carries a risk to some extent, right?
00:06:22.879 --> 00:06:23.279
Yes.
00:06:23.439 --> 00:06:25.439
So yeah, no, I I agree.
00:06:25.439 --> 00:06:31.680
I think we need to overall do a better job of how we frame that conversation for patients.
00:06:31.680 --> 00:06:43.920
I mean, it's it's not in a lot of cases
the the best approach to wait until somebody's age is high enough to push their 10-year risk into a into a treatment threshold.
00:06:43.920 --> 00:06:58.639
I mean, if there are other risk factors, um risk-enhancing factors, imaging evidence that suggests somebody's at a higher risk of disease over that 30-year horizon or you know, lifetime estimation of their risk, we should be intervening earlier.
00:06:58.959 --> 00:06:59.360
Sure.
00:06:59.360 --> 00:07:14.399
And one of the the risk-enhancing features, and I want to get to thresholds here in a little bit, we'll talk about that shortly, but one of the risk-enhancing features that had come up in the guidelines or really made a dominant point in Splash was the conversation around LP little a.
00:07:14.399 --> 00:07:17.920
And and you can, if you don't mind, to briefly talk what the suggestion was.
00:07:17.920 --> 00:07:28.480
But then obviously in the last several weeks, we've seen uh data come out from Novaris's trial that you know, preliminary data that suggests that it was there was not it did lower LP little, but no benefit.
00:07:28.480 --> 00:07:30.800
And maybe twofold question.
00:07:30.800 --> 00:07:34.560
Tell us about you know LP little a, what the risk is and what that is.
00:07:34.560 --> 00:07:43.519
And then now, given the light of the data we had, what do we do with this in conversations or how are you having that conversation with your patients now uh in terms of LP little a?
00:07:43.519 --> 00:07:45.839
Um, and then I'll have a secondary question of that.
00:07:45.839 --> 00:07:46.720
So let's start there.
00:07:46.720 --> 00:07:46.959
Yeah.
00:07:47.279 --> 00:07:47.439
Sure.
00:07:47.439 --> 00:07:53.199
Yeah, I think it's important to sort of separate these into two LP little A related topics.
00:07:53.199 --> 00:08:02.879
So we'll talk about LP little A and its importance as a predictor of cardiovascular risk and its incorporation into the updated guidelines.
00:08:02.879 --> 00:08:09.120
And then we can talk about the development of LP little A lowering targeted therapies.
00:08:09.120 --> 00:08:17.600
So for the guideline update, what you're alluding to is the recommendation for universal screening for LP little A for adults.
00:08:17.600 --> 00:08:21.839
So that was in the 2026 dyslipidemia guideline update.
00:08:21.839 --> 00:08:27.199
The National Lipid Association had a recommendation for universal testing in 2024.
00:08:27.199 --> 00:08:27.439
Right.
00:08:27.439 --> 00:08:36.399
But this is the first ACC AHA multi-society recommendation that every adult should have their LP little A level tested once.
00:08:36.399 --> 00:08:36.799
Right.
00:08:36.799 --> 00:08:56.240
And this stems from the really um large body of evidence that we have to support the role of LP little A in uh promoting athosclerotic cardiovascular disease and calcific aortic valve disease.
00:08:56.240 --> 00:09:00.960
And it is a highly prevalent, primarily inherited risk factor.
00:09:00.960
--> 00:09:06.480
So really, for most patients, all it takes is to get your LPA measured one time.
00:09:06.480 --> 00:09:08.080
It's genetically determined.
00:09:08.080 --> 00:09:13.200
So if it's elevated, it will have been that way essentially since you were born.
00:09:13.519 --> 00:09:16.559
And can you remind people what an elevated number would be?
00:09:17.039 --> 00:09:17.200
Yeah.
00:09:17.200 --> 00:09:30.480
So the guidelines specifically call out two thresholds for really beginning to worry about LP litol A-related risk, and that's at levels at or above 50 milligrams per deciliter or 125 nanomoles per liter.
00:09:30.480 --> 00:09:46.879
Elevated LP litol A is defined as above 30 milligrams per deciliter or 75 nanomoles per liter, but it's that higher threshold where we really begin to see more of a clear association between high LPA and future risk.
00:09:46.879 --> 00:09:57.279
If we're just talking about that higher risk range above 125 nanomoles per liter, we estimate that that affects about one in five people worldwide.
00:09:57.279 --> 00:10:01.120
Uh 20% of the population with a high LP little A.
00:10:01.120 --> 00:10:07.200
But in the US, for example, we test less than 1% of the population for LP little A.
00:10:07.200 --> 00:10:18.320
So what the guidelines are saying is that we have this highly prevalent inherited risk factor for cardiovascular disease that we're not testing very often, and we need to change that.
00:10:18.320 --> 00:10:23.840
You know, we need to make that a standard part of our risk assessment for our patients.
00:10:23.840 --> 00:10:24.480
Okay.
00:10:24.799 --> 00:10:25.360
Yeah.
00:10:25.360 --> 00:10:41.679
And so um kind of and we'll allude to this in both domains and lights, and and maybe as we carry through the conversation, how have you and your team, and we can talk about the treatment, the targets here in a minute, but how have you and your team begun to implement this process?
00:10:41.679 --> 00:10:44.000
To your point about the we're only testing about 1%.
00:10:44.320 --> 00:10:44.399
Right.
00:10:44.720 --> 00:10:47.600
What what is uh some strategies to do that?
00:10:47.600 --> 00:10:52.080
And then maybe also to lump that in, have you as you guys have uh adopted prevent score?
00:10:52.080 --> 00:10:57.279
Have you seen success in people updating uptaking and using prevent at this stage and how that's going?
00:10:57.279 --> 00:10:59.679
So a little bit about how you're implementing these tools.
00:11:00.399 --> 00:11:02.639
Yeah, so we're starting to use prevent.
00:11:02.639 --> 00:11:05.200
I'm seeing it more and more in my daily practice.
00:11:05.200 --> 00:11:09.440
It's become available as a dot phrase in our EHR.
00:11:09.440 --> 00:11:18.879
And so I'm starting to see uh primary care and my other colleagues at UCSD use a prevent score, you know, put that in their progress note when they see a patient.
00:11:18.879 --> 00:11:20.799
So we're seeing uptake of prevent.
00:11:20.799
--> 00:11:30.559
For LP Little A, you know, how do we bridge that gap between less than 1% of people tested and you know one in five people affected?
00:11:30.559 --> 00:11:35.039
I think we need a multi-pronged strategy to get there.
00:11:35.039 --> 00:11:41.360
I think having a guideline recommendation suggesting that every adult be tested goes a long way.
00:11:41.360 --> 00:11:42.159
It's a good start, right?
00:11:42.159 --> 00:11:43.519
It's a good start.
00:11:43.519 --> 00:11:46.240
So the messaging is very clear now.
00:11:46.240 --> 00:11:48.799
Everybody should be tested for LP little A.
00:11:48.799 --> 00:11:54.000
But I think there are some barriers that remain to implementing that recommendation.
00:11:54.000 --> 00:12:15.679
And those include things like access to tests, um, um interpretation of the results, so people being comfortable with how to uh interpret results and incorporate those results into an assessment of a patient's risk, confusion surrounding different units of measurement for LP little A.
00:12:15.679 --> 00:12:23.200
That's another thing that the field has struggled with because as I've you know just said, there's milligrams per deciliter and animals per liter.
00:12:23.200 --> 00:12:26.320
Everything we're reporting out is in both of those units.
00:12:26.320 --> 00:12:36.320
And so if you have different health systems, different clinics using different labs and different units of measurement, patients are getting information back that can sometimes be confusing.
00:12:36.320 --> 00:12:47.360
Um the same is true for clinicians getting information back and maybe getting LPA back in milligrams per deciliter from one lab and animals per liter from another lab.
00:12:47.360 --> 00:12:55.919
I also think that there's been some concern that even if you know LP little A, what can you do about it?
00:12:55.919 --> 00:12:56.240
Right.
00:12:56.240 --> 00:13:01.919
I mean without a targeted therapy to lower LP little A, is it actionable?
00:13:01.919 --> 00:13:07.600
I think it is very actionable, and I think the guidelines speak to that.
00:13:07.600 --> 00:13:21.200
You know, the guidelines say very clearly now that if you have elevated LP little A above those higher risk thresholds that I mentioned, the first step is to identify and treat all other modifiable risk factors for heart disease.
00:13:21.200 --> 00:13:35.679
I don't think there's any arguing that LP little A is clearly a predictor of risk, higher risk for atherosclerotic cardiovascular disease, and as I mentioned, calcific aortic valve disease.
00:13:35.679 --> 00:13:40.159
If you have high LP little A, your risk for those things is higher.
00:13:40.159 --> 00:13:55.600
The way to begin to offset that risk, although we're not sure yet if we can completely offset LPA-related risk, but the way to start getting at that overall risk for a patient is to treat those other modifiable risk factors.
00:13:55.600 --> 00:14:00.480
So if you know LP little A is high and you know a patient is at higher risk, that does change your management.
00:14:00.480 --> 00:14:12.399
It's actionable because you'll begin to take even more of an intensive treatment approach to things like LDL cholesterol, blood pressure, glucose control, you know, other cardiometabolic risk factors.
00:14:12.399 --> 00:14:16.960
That's the way that I think about how to interpret how to incorporate that now.
00:14:16.960 --> 00:14:38.559
And I think that messaging is something that we need to really we need to get out to more pay to more people, to more clinicians, to more patients, because that message that this is something worth knowing now that's actionable now is a big part of I think overcoming that gap between the recommendation for universal testing and currently low testing rates.
00:14:38.799 --> 00:14:39.279
Right, absolutely.
00:14:39.279 --> 00:14:43.600
And to your point, I think we see this a lot.
00:14:43.600 --> 00:15:00.480
Um you know, you have you end up testing, you have some with LP little A, and and to your point, adjusting or modifying the other things we can do, there's a lot of people who still even before you think about the little A, haven't had their other things optimized or managed, like their other lipid, you know, getting their LDL to the appropriate goal.
00:15:00.480 --> 00:15:05.039
And we'll talk about goals shortly, like even just we gotta even do the basics first, right?
00:15:05.039 --> 00:15:06.080
From that standpoint.
00:15:06.080 --> 00:15:07.360
So I agree with you on that.
00:15:07.759 --> 00:15:11.840
And there's evidence that the basics do help in patients with high LP little A.
00:15:11.840 --> 00:15:20.559
So we have some some nice um studies, for example, looking at the impact of uh achieving life simple seven.
00:15:20.559 --> 00:15:29.360
And if you have a you know healthier diet and lifestyle, even if you have high LP little A, we do see some meaningful reduction in risk.
00:15:29.360 --> 00:15:29.759
Yeah.
00:15:29.759 --> 00:15:34.879
It still matters to do these things to lower your risk of cardiovascular disease when your LPA is high.
00:15:34.879 --> 00:15:38.480
It goes a long way toward reducing your overall risk.
00:15:38.480 --> 00:15:44.080
And we see that with lowering of LDL cholesterol and other Apo B containing lipoproteins.
00:15:44.080 --> 00:15:53.120
I mean clearly doing doing that lowers cardiovascular risk in all of our patients at risk, including those with high LPA.
00:15:53.440 --> 00:15:53.679
Correct.
00:15:53.679 --> 00:16:07.440
And so just the messaging there, and I'm glad you were reiterating, is yes, you know, always lifestyle, doing your lifestyle activities and recommending those to our patients and continuing to do uh and promote those and help them achieve that process.
00:16:07.440 --> 00:16:18.559
And then of course, working through again our other, you know, just again starting with LDL and working that and making sure we're achieving and doing those
targets and applying those therapies and processes appropriately.
00:16:18.559 --> 00:16:25.759
So as as we were alluding to the second part, separating the question is okay, now you know what about therapies that modulate LP little A?
00:16:25.759 --> 00:16:32.320
What is the what is your uh filling or plan or trajectory at this particular juncture with that?
00:16:32.480 --> 00:16:49.039
So before diving into the horizon trial, I just want to point out that for LPA therapies, there there is one currently available FDA-approved therapy for LP little A, and that's lipoprotein aphoresis.
00:16:49.039 --> 00:16:49.279
Right.
00:16:49.279 --> 00:16:52.879
And that has an indication in select patients.
00:16:52.879 --> 00:17:08.000
But I think important to point out that for individuals with LP little A of 60 milligrams per deciliter or above who also have established cardiovascular disease and FH, there's a there's an FDA-approved indication to use aphoresis to treat LP little A.
00:17:08.000 --> 00:17:25.680
The other thing that is in the guidelines that I think is worth emphasizing is the potential role of using PCS-K9 inhibitor monoclonal antibodies in patients with high LP little A and established ASCBD not already at their LDLC and non-HDLC treatment targets with statins.
00:17:25.680 --> 00:17:37.359
Now, whether you consider a PCS-K9 inhibitor in LP little A lowering therapy, I think is something that we could discuss.
00:17:37.359 --> 00:17:44.400
I mean, it does have up to about a 20-25% reduction in LP little A.
00:17:44.400 --> 00:17:59.519
But really, where those guideline recommendations come from are post hoc analyses of the PCS-K9 inhibitor monoclonal antibody outcomes trials, so Fourier with EvolucuMab and the Odyssey outcomes trial with Alalocumab.
00:17:59.519 --> 00:18:12.079
And in post hoc analyses looking at those participants with the highest LPA levels, those individuals did significantly benefit from the use of PCS-K9 inhibitors.
00:18:12.079 --> 00:18:18.720
They experienced significant risk reduction for recurrent events, you know, as was the takeaway from those trials.
00:18:18.720 --> 00:18:25.440
And there was a signal that maybe there was some part of the risk reduction attributable to changes in LPA.
00:18:25.599 --> 00:18:26.240
Right.
00:18:26.559 --> 00:18:36.000
I think at the end of the day, you know, the take home from those trials, and I think it's it's why it's in the guidelines, is that those drugs worked for those patients.
00:18:36.000 --> 00:18:54.000
If you have a patient with ASCVD and they're on a statin and they're not yet at their LDLC or non-HDLC goal and they have high LP little A, we can point to data saying that those patients will benefit from PCS canine inhibitor monoclonal antibodies as an add-on.
00:18:54.240 --> 00:18:54.720
Right.
00:18:55.200 --> 00:19:04.640
That's what we have to work with today for LP little A, you know, in addition to, as I mentioned, just generally managing cardiovascular risk factors.
00:19:04.640 --> 00:19:14.799
But the field for LPA targeted therapies, you know, it it includes pelicarsin in the horizon trial.
00:19:14.799 --> 00:19:21.599
But it includes many other primarily RNA-based therapies.
00:19:21.599 --> 00:19:24.799
So other RNA targeted therapies.
00:19:24.799 --> 00:19:28.960
Pelicarsin, for example, is an antisense allegonucleotide.
00:19:28.960 --> 00:19:32.079
That's one form of an mRNA targeting therapy.
00:19:32.079 --> 00:19:44.880
It uh targets and um leads to the degradation of the LPA mRNA, the mRNA that codes for the APOA that's required for assembling the particle.
00:19:44.880 --> 00:19:54.240
Other drugs that are in phase three cardiovascular outcomes that are also RNA-targeted therapies for LPA are opasserin and lepidiccerin.
00:19:54.240 --> 00:20:00.880
Um, xerlaserin completed a phase two trial, but isn't in a phase three, like opasserin and lepidiccerin.
00:20:00.880 --> 00:20:02.160
Those are siRNAs.
00:20:02.160 --> 00:20:13.519
We can talk a little bit about how those are different from an antisense ligonucleotide, but the key differences are things like the frequency of dosing and the efficacy of LPA lowering.
00:20:13.519 --> 00:20:19.119
There's also an oral therapy, movalaplin, which is in a phase three outcomes trial.
00:20:19.119 --> 00:20:27.839
This is a drug that disrupts the interaction, the binding between APOA and the rest of the LP little A particle.
00:20:27.839 --> 00:20:32.319
So it prevents that final step, that assembly of the particle.
00:20:32.319 --> 00:20:39.839
That drug has been shown to lower LPA levels by about 80% or so, maybe a little bit higher.
00:20:39.839 --> 00:20:43.279
And it's in a phase three outcomes trial, as I mentioned.
00:20:43.279 --> 00:20:50.640
So that's the the current landscape of LPA targeted therapies in late-stage trials.
00:20:50.640 --> 00:20:58.480
I think in interpreting the results of the horizon trial, which means to preface, we don't have all the results yet either.
00:20:58.480 --> 00:20:59.359
Thank you.
00:20:59.359 --> 00:20:59.599
Yeah.
00:20:59.599 --> 00:21:01.920
We have the we have the top line result.
00:21:01.920 --> 00:21:08.480
Um and what we know is that the trial failed to meet its primary endpoint.
00:21:08.480 --> 00:21:13.519
So that is specifically what we know um about the top line result of Horizon.
00:21:13.519 --> 00:21:18.079
Um I'm happy to go into the No, I mean the big thing is to your point, you set up a very good stage.
00:21:18.160 --> 00:21:20.720
We have lots of therapies that are are are under investigation.
00:21:20.720 --> 00:21:23.759
This one particularly failed to meet its top line result.
00:21:23.759 --> 00:21:26.240
We know it changed levels.
00:21:26.240 --> 00:21:26.880
Correct.
00:21:26.880 --> 00:21:28.480
We we did get informed that.
00:21:28.480 --> 00:21:28.880
Yes.
00:21:28.880 --> 00:21:35.359
Um but we don't know you know what all all the the uh complete
data set looks like.
00:21:35.359 --> 00:21:43.839
And you know, I I guess right now it's all a little conjecture because we don't have that data, but is it did they did we maybe pick the wrong population?
00:21:43.839 --> 00:21:45.519
Is it something d else?
00:21:45.519 --> 00:21:52.400
And and of course we can't say that until the data comes out, but I think it's going to be interesting to have that conversation.
00:21:52.400 --> 00:21:59.759
And maybe my better question for you is and you kind of already answered it, is this people shouldn't be scared away from LP little A at this juncture?
00:21:59.759 --> 00:22:03.359
Just because of this top line result, right?
00:22:03.680 --> 00:22:03.839
Right.
00:22:03.839 --> 00:22:26.799
I think that's one very important takeaway is that everything that we've been discussing about the robust evidence behind LP little A as a contributor to risk of cardiovascular disease, its heritability, the importance of knowing your LPA measure and using that information to make treatment decisions, just globally lowering your cardiovascular risk, all that holds.
00:22:26.799 --> 00:22:49.519
I think we are still in this stage of figuring out whether going after LP little A with a targeted therapy adds uh adds to the risk reduction that we can achieve with those other um interventions that we use to lower somebody's cardiovascular risk.
00:22:49.519 --> 00:22:59.200
What I do think is important for listeners to appreciate are some of the distinctions between Horizon and the other outcomes trials that I mentioned.
00:22:59.200 --> 00:23:15.279
Um it's important to understand that not only are the drugs different, so in terms of their mechanism of action, the antisens ligonucleotide versus the SARNAs versus the oral inhibitor, but like you alluded to, there's differences in trial population.
00:23:15.279 --> 00:23:27.599
So whether that will be something that you know lends itself to further interpretation of horizon when we have the full data, I think we'll we'll see.
00:23:27.599 --> 00:23:41.039
But at least for now we can say that horizon was a trial of patients who'd had a cardiovascular event, so either a coronary event in the past, ischemic stroke, or PAD.
00:23:41.039 --> 00:23:47.039
And the primary endpoint for horizon was the composite of four-point mace.
00:23:47.039 --> 00:23:55.839
So looking at um death from cardiovascular causes, coronary events, ischemic stroke, PAD events.
00:23:55.839 --> 00:24:03.039
And as you mentioned already, we know that the drug effectively lowered LP litol A by about 80%.
00:24:03.039 --> 00:24:10.400
So what can we take away from a trial that didn't meet its primary endpoint with that information?
00:24:10.400 --> 00:24:22.720
We know that in that group, in this population of patients with established cardiovascular disease, with the drug that lowered LP little A by 80%, it didn't reduce the risk of four-point mace.
00:24:23.279 --> 00:24:23.759
More to come.
00:24:23.759
--> 00:24:24.240
Right.
00:24:24.640 --> 00:24:31.599
If you look at the other trials, yeah, they include slightly different, I think importantly different patient populations.
00:24:31.599 --> 00:24:39.200
So the opasserin trials, and I mentioned opasserin in a phase three outcomes trial, Oceana outcomes.
00:24:39.200 --> 00:24:42.079
It's essentially a coronary trial.
00:24:42.079 --> 00:24:58.240
So for inclusion there, participants need to have a history of coronary artery disease, but it doesn't include, as part of the entry criteria, stroke or PAD, and the primary endpoint is a composite endpoint for coronary events.
00:24:58.240 --> 00:24:58.960
Right.
00:24:58.960 --> 00:25:02.319
The LP little A for inclusion is a little bit higher.
00:25:02.319 --> 00:25:12.720
And alpasserin is a different drug in SIRNA, dosed every three months as opposed to once a month, with overall greater LPA lowering efficacy.
00:25:12.720 --> 00:25:23.039
Finally, both lepidiserin and now alpasserin are being studied in high-risk primary prevention, which that would be brand new.
00:25:23.039 --> 00:25:23.920
I mean, yeah, right.
00:25:24.079 --> 00:25:25.359
And that may be the key, right?
00:25:25.359 --> 00:25:26.079
We don't know.
00:25:26.079 --> 00:25:26.480
Yeah.
00:25:26.720 --> 00:25:40.559
We don't know, but I'm glad that you know we're going to be looking at not only the horizon population, high-risk um secondary prevention or secondary prevention population, but also primary prevention.
00:25:40.559 --> 00:25:41.119
Correct.
00:25:41.440 --> 00:25:46.960
Which I think is great to continue to move the needle towards back to our lifetime exposure risk, right?
00:25:46.960 --> 00:25:51.519
And and really thinking more about lifetime exposure and how we look at that and mitigate that.
00:25:51.519 --> 00:26:11.200
It's so refreshing to be looking at it in that domain and not and I get it as people are researching and developing, it mitigates a little bit of that risk in the development by picking a very high risk population, because you can definitely get the events you're looking for and study it and all the logistics of doing a research study, but it's refreshing for us to look at this from a primary prevention lens.
00:26:11.200 --> 00:26:14.319
So let me let me ask you a pivot a little different question.
00:26:14.319 --> 00:26:17.200
Uh I want to hear your how you approach this.
00:26:17.200 --> 00:26:19.440
I think this is an interesting construct that you always work with.
00:26:19.440 --> 00:26:24.160
Talking about um disease states that are inflammatory disease states.
00:26:24.160 --> 00:26:24.720
Okay.
00:26:24.720 --> 00:26:28.720
Uh, and we can talk about inflammation inflammation as a whole if you want to put that lens in it.
00:26:28.720 --> 00:26:38.400
But if you have a patient who has a history of HIV, rheumatoid arthritis, something to that effect, you know, we obviously know that that enhances your risk for event.
00:26:38.400 --> 00:26:43.519
How are you contextualizing that, especially after the scoring system or with other things?
00:26:43.519 --> 00:26:50.960
How are you how do you put those inflammatory diseases in your context when you're either having a conversation with a patient or if you're going to treat them at that point?
00:26:51.440 --> 00:26:52.720
Yeah, that's an important question.
00:26:52.720 --> 00:27:02.720
Part of what we should be thinking about when we are seeing a patient and we're we're really trying to understand everything that can put them at risk for cardiovascular events.
00:27:02.720 --> 00:27:11.519
Those fall outside of something like the prevent ASCBD equations and are included in the guidelines as risk-enhancing factors.
00:27:11.519 --> 00:27:24.480
So it's up to us as clinicians to find a way to incorporate that inflammatory risk into our overall assessment of that patient's risk and tailor our treatment recommendations accordingly.
00:27:24.480 --> 00:27:46.880
You know, I think that overall we should be intensifying treatment and setting more intensive treatment goals for individuals with some of the inflammatory diseases that you mentioned, so autoimmune or other inflammatory diseases where we know there's an increase in cardiovascular risk.
00:27:46.880 --> 00:27:52.480
And there's evidence to suggest that we can reduce that risk through more intensive lipid lowering.
00:27:52.480 --> 00:28:06.000
So, for example, with lowering LDL cholesterol or other Apo B containing lipoproteins, it may not be getting directly at the inflammatory risk as far as underlying mechanisms are concerned.
00:28:06.000 --> 00:28:13.680
But we know we can offset overall cardiovascular risk with more intensive lipid lowering therapies in those patients with inflammatory risk.
00:28:13.680 --> 00:28:14.400
Right.
00:28:14.400 --> 00:28:29.759
I think other things, so outside of the setting of having a known systemic inflammatory disease or something characterized by chronic inflammation, we do use HSCRP for risk ratification.
00:28:29.759 --> 00:28:32.319
That's in the updated guideline recommendation.
00:28:32.319 --> 00:28:43.519
So using an HSCRP measurement and finding that if it's over two milligrams per liter on more than one measurement, then that's going back to Jupiter days, the Jupiter trial days, right?
00:28:43.519 --> 00:28:49.279
But you can use that as another flag of a patient at higher overall risk.
00:28:49.279 --> 00:28:57.599
I mean, you have now identified some uh chronic low low grade inflammation that may be contributing to overall risk.
00:28:57.599 --> 00:29:10.000
I think what to do with that from a pharmacologic perspective, uh I don't have a straightforward approach to that currently, but I think it tells us more about an individual's risk.
00:29:10.000 --> 00:29:15.599
I think it often is tied in with other cardiometabolic risks.
00:29:15.599 --> 00:29:16.400
Correct.
00:29:16.400 --> 00:29:24.079
And you know, by that I mean
things like overweight obesity, metabolic syndrome, diabetes, and inflammation.
00:29:24.079 --> 00:29:28.480
So it's it's helping us to have a more comprehensive picture of that patient and their risk.
00:29:28.880 --> 00:29:30.640
And I appreciate you say that.
00:29:30.640 --> 00:29:32.720
That's actually really what I wanted to get towards with this.
00:29:32.720 --> 00:29:45.279
And again, talking about inflammation or treatment of inflammation and that whole piece, that's a separate can obeys nest that we won't kick today because there's other trials and other things that we won't go down that pathway and have that conversation.
00:29:45.279 --> 00:29:46.319
That's for another day.
00:29:46.319 --> 00:29:57.759
Uh but really what I wanted to get into, it's like how do you and you did this beautifully, you know, how do you contextualize that with the patient, especially when maybe they're I'll give you a a generic case example, right?
00:29:57.759 --> 00:30:07.839
You have a patient who's an intermediate risk prevent score, and maybe they have an elevated LP little A, like we were just talking about, but then they also have a history of controlled HIV, for example.
00:30:07.839 --> 00:30:10.960
And then so where are you what what is your now?
00:30:10.960 --> 00:30:13.359
Are you going to recommend them to get a CAC?
00:30:13.359 --> 00:30:15.279
Are you going to go ahead and push them towards treatment?
00:30:15.279 --> 00:30:22.240
Like what how do you approach that patient who's like, well, they're like intermediate for everything, and they could be, but they're maybe they're hesitant.
00:30:22.240 --> 00:30:27.519
What is going to help you can do the shared decision-making process to lead them that way, right?
00:30:27.839 --> 00:30:29.200
It's such a critical question.
00:30:29.200 --> 00:30:31.279
I mean, that is our everyday, right?
00:30:31.279 --> 00:30:49.839
I mean, we need to that's that's the moment for us to have that conversation, that shared decision making with the patient, where there is some uncertainty, or we need to meet the patient, you know, where they are and they're they're thinking about their risk or their readiness to do something like startostatin or the lipidlorine therapy.
00:30:49.839 --> 00:30:53.759
And so I think it really does depend on how that conversation goes.
00:30:53.759 --> 00:30:59.200
I mean, we can use things like estimates of 10-year risk for ASCBD.
00:30:59.200 --> 00:31:03.039
Is that helpful in that conversation with a patient?
00:31:03.039 --> 00:31:10.799
Is you know, describing their risk more generally in terms of the fact that inflammation, we know, is a risk-enhancing factor.
00:31:10.799 --> 00:31:13.920
Is that enough to make that decision together?
00:31:13.920 --> 00:31:14.880
Often it is.
00:31:14.880 --> 00:31:20.960
I mean, I think if you say that, you know, these are the guideline recommendations, I think that you'll benefit from this.
00:31:20.960 --> 00:31:25.440
It will lower
your 10-year risk, your lifetime risk of having a heart attack or stroke.
00:31:25.440 --> 00:31:30.400
I think that's um often enough for that conversation.
00:31:30.400 --> 00:31:42.640
But I also think that there's an important role for things like coronary artery calcium scoring as a tool for further risk stratification and often further individualizing that risk assessment.
00:31:42.640 --> 00:31:44.799
So I think it is very helpful for that.
00:31:44.799 --> 00:31:54.240
I think that it's always important to interpret coronary artery calcium scoring results with the individual patient in mind, though, as well.
00:31:54.240 --> 00:32:06.480
I mean, some patients are not as well represented in some of the studies that have been used to determine how we incorporate calcium scores into an estimate of risk.
00:32:06.480 --> 00:32:34.079
So, you know, for example, I think in these cases of patients with systemic forms of inflammation, we know less about how a calcium score may perform than in the general population of patients, you know, more broadly represented in the the cohorts that were used to understand how calcium scoring helps to modify that assessment of risk.
00:32:34.079 --> 00:32:54.640
That said, I think a calcium score is one of the most useful tools that we have today in cutting through some of the uncertainty that often comes with risk calculators and you know our ability to oftentimes qualitatively incorporate risk-enhancing factors into that.
00:32:54.640 --> 00:32:59.200
If you have a calcium score of zero, that means something.
00:32:59.200 --> 00:33:03.519
If you have a non-zero score, you know, that means something too.
00:33:03.519 --> 00:33:08.240
And um how high that non-zero calcium score means something.
00:33:08.240 --> 00:33:20.319
Even if the estimates are lacking in precision sometimes for an individual patient's situation, it still gives us, I think, a very useful tool to to move that patient into different levels of risk.
00:33:20.640 --> 00:33:20.880
Yeah.
00:33:20.880 --> 00:33:21.839
Very good.
00:33:21.839 --> 00:33:24.480
And let's kind of transition briefly.
00:33:24.480 --> 00:33:28.799
We won't go into every type of new threshold.
00:33:28.799 --> 00:33:32.160
Obviously, you know, we talked very heavily in the previous episode.
00:33:32.160 --> 00:33:46.480
I do refer people back to my conversation when the guidelines came out with Dave and Joe regarding um you know the the new thresholds and what we're looking at and going back to you, but more kind of generally and high-level.
00:33:46.480 --> 00:33:56.799
What what what is exciting or or maybe rejoicing for you to go back to having a a kind of a threshold-based target?
00:33:56.799 --> 00:34:06.559
And and how do you think going back to my implementation question, how do we get people to start getting back into that mindset and working into that that direction?
00:34:06.720 --> 00:34:09.360
So yeah, no, I think it's a great thing for the field.
00:34:09.360 --> 00:34:25.679
I think it's gonna lead to more of our patients being treated, um, treating to lower targets, lower levels of LDL cholesterol than you might otherwise achieve if your goal was to start a certain intensity of statin therapy.
00:34:25.679 --> 00:34:35.360
I mean, now we have a lot of tools that can help us to get patients to lower levels of LDL cholesterol and related lipoprotein targets.
00:34:35.360 --> 00:34:50.239
And so I think that you know it's really now in line with the um, you know, the totality of the evidence that we have around the benefits of lowering LDL cholesterol and these related measures for preventing heart disease.
00:34:50.239 --> 00:34:50.719
Right.
00:34:50.719 --> 00:34:57.360
So yeah, I'm I'm very grateful for the reintroduction of these targets.
00:34:57.360 --> 00:35:02.239
And I think that from an implementation standpoint, it's gonna be helpful.
00:35:02.239 --> 00:35:09.760
I think everybody, clinicians, patients, benefit from having a target, something to something we're we're reaching for now.
00:35:10.079 --> 00:35:10.239
Yeah.
00:35:10.239 --> 00:35:13.679
Have you guys already adopted or made your own quality metrics around this?
00:35:13.679 --> 00:35:24.960
I know at some point we will probably have uh you know value-based metrics or something that adapts back to this, but being proactive, have you guys already kind of implemented some quality-based metrics around achieving these targets?
00:35:25.360 --> 00:35:28.559
Yes, yeah, I I've seen that come through at UCSD.
00:35:28.559 --> 00:35:28.880
Okay.
00:35:28.880 --> 00:35:38.960
So um yeah, just within the past couple months, at least our own internal internal measurements are being um reported along with other quality measures.
00:35:38.960 --> 00:35:43.599
Yeah, there's an LDL in secondary prevention measure that we're very good.
00:35:43.599 --> 00:35:43.840
Yeah.
00:35:44.000 --> 00:35:46.800
So I have two more questions and we'll we'll kind of near the wrap up.
00:35:46.800 --> 00:35:54.480
So obviously, one of the other big things this year is oral PCSA9 inhibitors that have come out, uh, or the first oral PCSA9 inhibitor.
00:35:54.480 --> 00:36:16.320
How are you thinking about when and and where you're using or choosing an oral an oral agent versus and I know there's lots I have my own perceptions and commentary, but just in your like when you're in clinic now, what is your approach or conversation about this, or how are you deciding you know which avenue to go down?
00:36:16.719 --> 00:36:17.360
Yeah.
00:36:17.360 --> 00:36:25.840
It's a great question, something that comes up every day, you know, now that we have all these tools, as I mentioned, we have a lot of tools to work with, which is amazing.
00:36:25.840 --> 00:36:37.119
I mean, it's a great time to be in this field and be able to respond to an updated guideline recommendation that we need to get patients to goal targets because we have really effective tools
to get there.
00:36:37.119 --> 00:36:38.079
That we need to use.
00:36:38.079 --> 00:36:39.599
That we need to use.
00:36:39.599 --> 00:36:40.159
Exactly.
00:36:40.159 --> 00:36:52.559
So with PCS canan inhibitors, the way that I usually frame it for patients is based on things like their treatment target and how far away we are from that.
00:36:52.559 --> 00:37:08.719
Um, given that there are some differences in the expected efficacy of the different PCS canan inhibitors, a patient's preference for an injectable versus an oral therapy, that's important, plus the frequency of injections.
00:37:08.719 --> 00:37:10.639
All of those come into play.
00:37:10.639 --> 00:37:14.559
The, you know, the side effect profiles are things that we talk about as well.
00:37:14.559 --> 00:37:18.320
And then, frankly, I mean, access is a big one.
00:37:18.320 --> 00:37:28.800
So we talk about the differences between these drugs and the data behind them and their efficacy and safety, but then at the end of the day, what can you actually access?
00:37:28.800 --> 00:37:30.480
What will your insurance approve?
00:37:30.480 --> 00:37:32.159
What will they help pay for?
00:37:32.159 --> 00:37:42.239
So I think that the oral PCS-KNA inhibitor is definitely a welcome addition to that toolkit that we have.
00:37:42.239 --> 00:37:55.360
There certainly are patients who have been hesitant to use PCS Canine inhibitors as injectable therapies, especially as self-administered subcutaneous injections.
00:37:55.360 --> 00:38:05.280
Um, I think that you know enlicitide is what we're talking about as the first FDA-approved oral PCS Canine inhibitor.
00:38:05.280 --> 00:38:14.000
And I think it has an efficacy profile that's similar to other PCS Canine inhibitors, a favorable safety profile.
00:38:14.000 --> 00:38:16.800
And so I go over those things with patients.
00:38:16.800 --> 00:38:24.960
Um, we do also talk about the fact that there are still trials ongoing with some of our PCS canine inhibitors, right?
00:38:24.960 --> 00:38:30.079
So Evalucumab, Ballarocumab have been around longer.
00:38:30.079 --> 00:38:37.519
They've they have cardiovascular outcomes trials, and that includes you know, recent data from Vesalius for Evalucumab.
00:38:37.519 --> 00:38:44.800
Enclycerin is in outcomes trials, and licitide is in outcomes trials.
00:38:44.800 --> 00:38:52.000
But you know, I think at the end of the day, it again comes down to that personalized decision making.
00:38:52.000 --> 00:39:02.960
I think by the time you get toward the end of that conversation with the patient, you're getting a pretty clear sense of what's acceptable to them, what their preferences are, putting all those things together.
00:39:02.960 --> 00:39:12.239
Um, and again, thinking through where this fits into their other treatment, the other meds, their treatment target, what's it gonna take to get there?
00:39:12.559 --> 00:39:12.800
Sure.
00:39:12.800 --> 00:39:14.000
You know, I it's funny.
00:39:14.000
--> 00:39:17.679
Obviously, one of the themes we've touched upon here is personalization.
00:39:17.679 --> 00:39:21.119
Like it's you know, living management has become way more personal.
00:39:21.119 --> 00:39:31.920
Not that it wasn't, but just given the breadth of things we have to choose from and goals and how we're gonna adjust to to um risk-stratify and and be able to further risk stratify people.
00:39:31.920 --> 00:39:36.320
It and then of course, when you get to treatment, you have different options and things that you can talk to them about, right?
00:39:36.320 --> 00:39:37.679
You know, even given their own ranger.
00:39:37.679 --> 00:39:47.119
I was having this conversation the other day with someone, I think there was also an article in the New York Times that talked about you know people overcoming their fear of injections to do GLP1s, for example.
00:39:47.119 --> 00:39:55.679
But then you think about you know, you have PCS9s, or and it feels like more and more injectable therapies are coming out there.
00:39:55.679 --> 00:40:00.719
I'm like, are are people going to be willing to accept eight different types of injections, right?
00:40:00.719 --> 00:40:08.320
Like as we continue, like what is that going to look like if we're now so injection heavy as a treatment for different disease states?
00:40:08.320 --> 00:40:12.320
Because other there are other cardiovascular agents coming down the line that are injectables, right?
00:40:12.320 --> 00:40:12.719
Sure.
00:40:12.719 --> 00:40:18.800
And so it's like uh yes, and while you don't have to inject them every day or it's like you know weekly, it's just like still the thought.
00:40:18.800 --> 00:40:19.599
That's a lot of injections.
00:40:22.239 --> 00:40:33.679
Actually, in patients who are on a GLP1 injection already, um, one of the things about prescribing a monoclonal antibody is that it's uh only every other week instead of every week.
00:40:33.679 --> 00:40:36.880
And so some patients I've I've seen are are like, oh, okay.
00:40:36.880 --> 00:40:38.960
Yeah, it takes not every week, just every other week.
00:40:38.960 --> 00:40:39.840
Right, right, right.
00:40:39.840 --> 00:40:40.320
Okay.
00:40:40.320 --> 00:40:40.719
Yeah.
00:40:41.039 --> 00:40:42.320
It's a little trade-off, right?
00:40:42.639 --> 00:40:44.719
Yeah, but I know I I agree with you completely.
00:40:44.719 --> 00:41:01.760
I think all of that, I mean, like we've always had to think through polypharmacy or multiple medications, especially ones that patients have to get you know insurance approval for that would otherwise have you know high out-of-pocket costs for patients.
00:41:01.760 --> 00:41:06.159
I think we need to really be thoughtful in the way that we recommend these medications.
00:41:06.159 --> 00:41:10.159
So they're they're really getting the most benefit out of those that we recommend.
00:41:10.480 --> 00:41:10.800
Absolutely.
00:41:10.800 --> 00:41:13.760
And this actually brings me to the last clinical question.
00:41:13.760 --> 00:41:17.760
And of course, I'm biased because I'm I'm a pharmacist.
00:41:17.760 --> 00:41:20.960
So this is how how how are you using pharmacists in your clinic?
00:41:20.960 --> 00:41:21.840
Or what does that look like?
00:41:21.840 --> 00:41:23.119
Do you have pharmacists in your clinic?
00:41:23.119 --> 00:41:24.239
Are you working with pharmacists?
00:41:24.239 --> 00:41:28.239
How does that work, or how do you employ or engage with the pharmacy team?
00:41:28.800 --> 00:41:37.039
So we have pharmacists integrated into our cardiovascular clinic at UCSD, and they play a number of roles.
00:41:37.039 --> 00:41:45.119
So doing things like providing support to the entire clinic for medication refills and authorizations.
00:41:45.119 --> 00:41:55.360
And then there are some groups within cardiology where pharmacists are even more integrated and they're seeing patients, you know, in our heart failure subspecialty group, for example.
00:41:55.360 --> 00:42:03.920
But I think that having pharmacists more and more integrated into our everyday care of patients is something we need to strive for.
00:42:03.920 --> 00:42:08.719
I mean, I I would love to have even more support than we do.
00:42:08.719 --> 00:42:40.400
I think pharmacists can really help us to optimize care delivery for patients, can help um can help help us in these conversations, these nuanced conversations about risks, benefits, um monitoring side effects, making dose adjustments, following up on efficacy with things like you know, repeat lipid panels, um, so that we can stay within guideline recommendations for when to repeat labs and titrate meds.
00:42:40.400 --> 00:42:44.480
I mean, it's um a a huge contribution.
00:42:44.480 --> 00:43:07.599
And I think like you've said, in this era of having an expanding toolkit to work with in lipidology, I think having pharmacists uh involved in um helping us to to really get these new medicines to the right patients, uh, I think that's that's a huge, a huge role that pharmacists can play.
00:43:07.920 --> 00:43:08.320
Absolutely.
00:43:08.320 --> 00:43:09.519
Well, I appreciate that.
00:43:09.519 --> 00:43:21.679
Um just kind of the last question we we have is a non-clinical question, is if uh any good books, TV shows, podcasts, something that you would recommend that you've enjoyed in the last several months?
00:43:23.679 --> 00:43:25.519
Oh, that's that's a good question.
00:43:25.519 --> 00:43:39.599
Um, I uh I read I read a book just really recently, um, The Mysterious Case of Rudolf Diesel.
00:43:39.599 --> 00:43:40.239
Okay.
00:43:40.239 --> 00:43:44.239
And Diesel is the inventor of the Diesel engine.
00:43:44.239 --> 00:43:44.960
Right, yes.
00:43:44.960 --> 00:43:49.119
And his his story is really interesting.
00:43:49.119 --> 00:44:01.679
It's actually um all about you know his invention and trying to figure out how that's going to work its way into the fabric of society and do something good for humanity.
00:44:01.679 --> 00:44:20.079
The diesel engine through things like World War One didn't and its adoption into you know machines used for war didn't really work out the way that he had hoped, in terms of trying to invent something that was gonna be for the good of all humanity, but it's a it's a really interesting story.
00:44:20.239 --> 00:44:28.960
Oh, it's a f I mean it's an interesting story about the con yeah, the the the narrative of what the hopes are, but how it is used and what the you know it's fascinating.
00:44:29.360 --> 00:44:30.239
How we invent things, yeah.
00:44:30.239 --> 00:44:34.559
When we invent things, how do we get these things into society in the right way?
00:44:35.039 --> 00:44:35.760
And how are they used?
00:44:35.760 --> 00:44:36.559
Yeah, exactly.
00:44:36.559 --> 00:44:37.119
Interesting.
00:44:37.119 --> 00:44:38.000
Yes, very good.
00:44:38.000 --> 00:44:38.880
I uh Dr.
00:44:38.880 --> 00:44:40.960
Michael Wiggleson, thank you so much for being here.
00:44:40.960 --> 00:44:41.840
This was outstanding.
00:44:41.840 --> 00:44:49.599
It's always good to hear the lens of our our our physicians and and team leads that are doing this and and how we work through this.
00:44:49.599 --> 00:44:59.599
So I appreciate you you being here and I appreciate for the NLA for letting us do this joint effort and and and just you you're the incoming president or the president now of NLA, right?
00:44:59.599 --> 00:44:59.920
Correct?
00:44:59.920 --> 00:45:01.119
Are you going to be the president?
00:45:01.920 --> 00:45:04.559
I'm on the executive council of the council of the NLA.
00:45:04.559 --> 00:45:05.440
The NLA.
00:45:05.679 --> 00:45:05.920
Thank you.
00:45:05.920 --> 00:45:06.800
Very good.
00:45:06.800 --> 00:45:10.159
So uh as always, like, subscribe.
00:45:10.159 --> 00:45:12.000
If you like this content, please let us know.
00:45:12.000 --> 00:45:16.559
We'll continue to uh produce and do different things, but I appreciate this.
00:45:16.559 --> 00:45:18.079
More to come on lippets.
00:45:18.079 --> 00:45:21.519
I think if I'm not mistaken, Horizon is going to present it at AHA.
00:45:21.599 --> 00:45:23.119
If I'm that's I think that's what we're expecting.
00:45:23.280 --> 00:45:26.000
Okay, so we will definitely have follow-up to see.
00:45:26.000 --> 00:45:32.000
All right, thank you all, and please enjoy and come back and hear us in a few weeks with a new episode.
00:45:32.000 --> 00:45:33.119
Thank you.